{
  "docId": "019de070-2277-75da-968a-7dffc3addc7d",
  "docSlug": "9a22f83671fc7371cae4ff7d98099963",
  "documentTitle": "Fusion Pharmaceuticals | IPO Presentation Deck | 49 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 49,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "The slide uses a human body diagram to visually represent the systemic nature of the target.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-2277-75da-968a-7dffc3addc7d/23",
  "deckHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d",
  "deckJsonHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d.json",
  "deckAnchorHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.03,
        "y": 0.435
      },
      "kind": "callout",
      "text": "Target Broadly expressed in tumor cells",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16fbeab6-6788-422b-83e2-47b8d407de7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.18,
        "x": 0.28,
        "y": 0.2
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0217e29a-6a4a-4f90-9d1e-d5c181e09631",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.35,
        "x": 0.52,
        "y": 0.2
      },
      "kind": "table",
      "text": "Ovarian 100%, Bladder 100%, Sarcomas 90%, Head and Neck 62%, Prostate 62%, NSCLC 59%, Pancreatic 57%, Colorectal 50%, Liver 50%, Breast 47%, Small Cell Lung 43%, Esophagus 40%, Renal 36%, ACC 36%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2396d150-a9d4-48ac-907f-b93e78557805",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 1,
        "x": 0,
        "y": 0.93
      },
      "kind": "title",
      "text": "A multi-tumor targeted radiopharmaceutical with potential for broad clinical utility",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f65d047-e7b7-4d7f-bb57-d57a9cd41062",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "IGF-1R Is Over-Expressed On Multiple Tumor Types",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e03ee2c-1aa3-4411-976e-50fd02ec8dd2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "926c16d8-bf63-4c4f-99f6-8984aae404d8",
      "evidence": "Ovarian 100%, Bladder 100%, Sarcomas 90%, Head and Neck 62%, Prostate 62%, NSCLC 59%, Pancreatic 57%, Colorectal 50%, Liver 50%, Breast 47%, Small Cell Lung 43%, Esophagus 40%, Renal 36%, ACC 36%",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "evidence-matrix",
      "slug": null,
      "matchId": "db0413f7-cbb3-42ee-a457-2e7949021ae3",
      "evidence": "Presents a list of tumor types and their corresponding expression percentages to justify clinical utility.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 23,
      "from": 23,
      "beatId": "dfd887a8-24cb-425d-8dbe-174bae96e44b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The deck presents the problem of limited treatment options for cancer patients.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 28,
      "from": 19,
      "beatId": "808eda63-f5f8-4631-9599-1a2134d2ac37",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents data and results from Fusion Pharmaceuticals' clinical trials, demonstrating its progress and potential.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 23,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f2bba293-ab4d-41e5-a4d1-dfee987f7956",
      "evidence": "The deck presents data on the limitations of current treatment options and the potential benefits of Fusion Pharmaceuticals' approach.",
      "position": 0,
      "objective": "What are the consequences of not adopting Fusion Pharmaceuticals' targeted therapies?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}